Wave Life Sciences (WVE) Stock Crashes 30% Despite Calling Obesity Trial Data “Positive”

TLDR

• Wave Life Sciences stock fell 30% Thursday after releasing interim Phase 1 data from its INLIGHT obesity trial
• A single 240mg dose of WVE-007 produced a 14% placebo-adjusted reduction in visceral fat over six months
• Trial participants had a lower average BMI (32) than is typical for obesity studies, limiting direct comparison to rivals
• Jefferies maintained its Buy rating and $28 price target on WVE heading into the data release
• Wave plans to start Phase 2a of INLIGHT in Q2 2026, targeting higher-BMI patients with comorbidities

Wave Life Sciences released interim Phase 1 data from its INLIGHT trial on Thursday, and the market wasn’t impressed. The stock dropped 30% on the day despite results the company framed as positive.

Wave Life Sciences Ltd., WVE

The data covered WVE-007, a treatment for obesity. A single 240mg dose produced a placebo-adjusted 14% reduction in visceral fat over six months in participants with a mean BMI of 32 kg/m².

The company also reported a 16.5% improvement in visceral fat-to-muscle ratio from baseline. Lean mass increased 2.4%, waist circumference fell 3.3%, and body weight dropped 0.9% on a placebo-adjusted basis.

WVE-007 was well tolerated up to 600mg. There were no treatment discontinuations or severe adverse events. Serum Activin E reductions held through at least seven months, supporting the potential for once or twice-yearly dosing.

The catch? The average BMI in this cohort was 32 — well below the 37 typically seen in Phase 2 and 3 obesity trials. That makes comparisons to other drugs in development harder to make.

Wave compared WVE-007’s visceral fat results to weekly semaglutide from a separate Phase 2 trial. That semaglutide study enrolled patients with higher BMI, so the comparison raised eyebrows.

Investors were likely weighing those limitations against the backdrop of a highly competitive obesity drug market currently led by Novo Nordisk and Eli Lilly.

Phase 2a Incoming

Wave plans to kick off the Phase 2a portion of INLIGHT in Q2 2026. That study will enroll patients with a BMI of 35–50 with comorbidities — a more typical obesity trial population.

The company expects the higher-BMI cohort to show stronger body composition and weight loss results. Data from that study will inform Wave’s development strategy across obesity, MASH, type 2 diabetes, and cardiovascular disease.

Just a day before the data drop, Jefferies had reiterated its Buy rating and $28 price target on WVE, citing the RNA editing approach and the INHBE program as key drivers.

Analyst Roger Song flagged potential advantages of Wave’s platform: no off-target editing, a cleaner safety profile, and durable effects with convenient repeat dosing.

Other Pipeline Updates

Separately, Wave regained full rights to WVE-006 from GSK. The company will present a poster at ADA and expects to release 400mg multiple ascending dose and 600mg single ascending dose updates in May.

Mizuho raised its price target on WVE to $27 from $22 earlier this year, maintaining an Outperform rating after Wave took full ownership of WVE-006.

Wave also reported Q4 and full-year 2025 earnings recently, noting financial pressure from the end of a major collaboration. Revenue beat forecasts, but EPS missed expectations.

The company holds more cash than debt on its balance sheet, according to InvestingPro data.

Data from the RestorAATion-2 trial of WVE-006 is set to be presented at the American Thoracic Society International Conference in 2026, covering the 400mg multidose and 600mg single-dose cohorts.

The post Wave Life Sciences (WVE) Stock Crashes 30% Despite Calling Obesity Trial Data “Positive” appeared first on CoinCentral.